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Abstract: BACKGROUND: Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treat-
ment of patients with metastatic melanoma and non-small cell lung cancer (NSCLC). Despite important
clinical benefits, these therapies are associated with a diverse spectrum of immune-related adverse events
(irAEs) that are typically transient, but occasionally severe or even fatal. CASE PRESENTATION: This
autopsy case illustrates that clinically overt irAEs may represent only a fraction of the total spectrum
of immune-related organ pathology in patients treated with immune checkpoint inhibitors. We report a
comprehensive analysis of systemic irAE pathology based on the autopsy of a 35-year-old female patient
with metastatic melanoma treated first with ipilimumab and then nivolumab. The clinical course was
characterized by a mixed tumor response with regression of skin and lung metastases and fatal progres-
sion of metastatic disease in the small bowel, peritoneum and brain. During therapy with ipilimumab,
radiographic features of immune-related pneumonitis were noted. The autopsy examination established
a sarcoid-like granulomatous reaction of the lung, pulmonary fibrosis and diffuse alveolar damage. Im-
portantly, a clinically unapparent but histologically striking systemic inflammation involving the heart,
central nervous system, liver and bone marrow was identified. Severe immune-related end-organ damage
due to lymphocytic myocarditis was found. CONCLUSIONS: Autopsy studies are an important measure
of quality control and may identify clinically unapparent irAEs in patients treated with immunotherapy.
Pathologists and clinicians need to be aware of the broad spectrum of irAEs for timely management of
treatment-related morbidity.
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Abstract
Background: Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and
programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic
melanoma and non-small cell lung cancer (NSCLC). Despite important clinical benefits, these therapies are
associated with a diverse spectrum of immune-related adverse events (irAEs) that are typically transient, but
occasionally severe or even fatal.
Case presentation: This autopsy case illustrates that clinically overt irAEs may represent only a fraction of the total
spectrum of immune-related organ pathology in patients treated with immune checkpoint inhibitors. We report a
comprehensive analysis of systemic irAE pathology based on the autopsy of a 35-year-old female patient with
metastatic melanoma treated first with ipilimumab and then nivolumab. The clinical course was characterized by a
mixed tumor response with regression of skin and lung metastases and fatal progression of metastatic disease in
the small bowel, peritoneum and brain. During therapy with ipilimumab, radiographic features of immune-related
pneumonitis were noted. The autopsy examination established a sarcoid-like granulomatous reaction of the lung,
pulmonary fibrosis and diffuse alveolar damage. Importantly, a clinically unapparent but histologically striking
systemic inflammation involving the heart, central nervous system, liver and bone marrow was identified. Severe
immune-related end-organ damage due to lymphocytic myocarditis was found.
Conclusions: Autopsy studies are an important measure of quality control and may identify clinically unapparent
irAEs in patients treated with immunotherapy. Pathologists and clinicians need to be aware of the broad spectrum
of irAEs for timely management of treatment-related morbidity.
Keywords: Melanoma, Immunotherapy, Immune checkpoint inhibitors, Antibody, Ipilimumab, Nivolumab,
Autoimmunity, Autopsy, Anti-tumor T cell response
Background
Four years after the approval of the first checkpoint inhibi-
tor ipilimumab (anti-CTLA-4) for advanced melanoma in
2011, cancer immunotherapy is now considered one of the
pillars of cancer therapy [1]. Immune checkpoint inhibitors
interacting with the PD-1/PD-L1 axis were recently ap-
proved by the Food and Drug Administration (FDA) based
on successful large randomized controlled clinical trials [2]
of patients with metastatic melanoma [3, 4], non-small cell
lung cancer (NSCLC) [5, 6] and renal cell cancer [7]. There
is a broad activity in different cancer types including DNA
mismatch repair deficient colorectal cancer [8], ovarian
cancer [9] and treatment-refractory Hodgkin lymphoma
[10]. Durable responses with survival plateaus have been
reported. As a consequence, the number of patients treated
with immunotherapy is expected to increase. Both patholo-
gists and clinicians therefore need to be increasingly aware
of the unique spectrum of tissue reactions associated with
immune checkpoint inhibitor therapy to guide patient
management in daily practice.
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Efficacious cancer treatment with checkpoint inhibitors
can cause systemic immune activation that may poten-
tially lead to tissue damage. Common adverse reactions
affect the skin, gastrointestinal tract, liver, endocrine
organs and lungs, ranging from clinically unapparent to
severe immune-mediated organ damage [11]. The severity
of irAEs clearly correlates with the dose and length of
anti-CTLA-4 and anti-PD-1 treatment [12]. In particular,
combination therapy with several immune checkpoint
inhibitors may cause more adverse drug reactions than
monotherapy [13]. Interestingly, a weak correlation of the
severity of irAEs with treatment response has also been
described [14]. Consequently, irAEs may be more com-
mon in long term survivors. Several case reports have pre-
viously illustrated the diverse clinical spectrum of irAEs
including diffuse alveolar damage and immune mediated
pneumonitis [15], myocarditis [16], arthritis [17], severe
skin toxicity [11], hypophysitis and meningoencephalitis
[18]. Due to the strong immune activation by checkpoint
inhibition, it may be assumed that less severe adverse drug
reactions accompany overt irAEs in patients treated with
immunomodulators and may contribute to long term
treatment-related organ damage. Even though analyses of
systemic organ pathologies based on autopsy studies
following treatment with immune checkpoint inhibitors
are an important measure of quality control, postmortem
studies are currently lacking in the literature. Here we re-
port a comprehensive analysis of systemic irAE pathology
based on the autopsy of a 35-year-old female patient with
metastatic melanoma sequentially treated with ipilimumab
and nivolumab (Fig. 1).
Case presentation
In August 2012, the patient presented with a malignant
melanoma arising from a congenital nevus in the right
dorsum of the foot which had been diagnosed following
excisional biopsy at a local primary care physician (Breslow
thickness 1.7 mm, Clark Level IV) (Fig. 2a). A wide excision
of the lesion with adequate safety margins was performed
and the patient was lost to follow up. In August 2013, one
year after the primary excision, a local recurrence of
malignant melanoma was detected (diameter 1.55 mm,
infiltration depth 1.55 mm). Histopathological examination
revealed an in-transit metastasis (diameter 3 mm) in the
subcutaneous tissue which focally reached the deep surgical
margin (Fig. 2b). Re-excision with adequate safety margins
and a sentinel lymph node dissection was performed, iden-
tifying melanoma micrometastases in two out of four
lymph nodes examined (Fig. 2c). Following a positive preg-
nancy test, active surveillance was maintained.
One year after the first recurrence and 4 months after
delivery, the patient presented to her dermatologist for a
follow up examination. A positron-emission tomography
was performed revealing enlarged and enhancing right
inguinal lymph nodes with soft tissue extension. Three
weeks later, multiple skin metastases on the right leg were
detected and confirmed as melanoma by punch biopsy
(Fig. 2d). Molecular analysis of one skin metastasis was
performed at an outside institution. No potentially target-
able BRAF, NRAS or c-KIT mutations were reported.
First line therapy with dacarbazine every 3 weeks for
5 cycles was initiated in November 2014. The patient
experienced disease progression under dacarbazine treat-
ment with increasing size and number of skin, nodal and
soft tissue metastases as well as newly detected metasta-
ses in both lungs (Fig. 3a). As dacarbazine can cause
hematopoietic depression with severe leukocytopenia
and thrombocytopenia, the differential blood counts
were closely monitored. After the third cycle of dacarba-
zine, hematological studies showed significantly reduced
neutrophil counts. No other hematological abnormalities
were detected. Liver, renal and thyroid function was
normal (see Additional file 1: Table S1 for laboratory
studies).
Following completion of the fifth cycle of dacarbazine,
the patient was treated with ipilimumab at 3 mg/kg every 3
weeks for four cycles from February to April of 2015.
Radiotherapy to the soft tissues and nodes in the left
Fig. 1 Time axis. Line graph illustrating disease progression and therapeutic intervention between initial diagnosis in August 2012 and death from
metastatic melanoma in September 2015
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inguinal region was administered (60Gy, 30 fractions,
March to April 2015). After completing the fourth cycle of
ipilimumab in the end of April 2015, computed tomog-
raphy showed evidence of a mixed tumor response with re-
gression of pulmonary and skin metastases. The
appearance of bilateral pulmonary ground glass opacities
was noted (Fig. 3b). The patient was closely monitored. As
there was no evidence of reduced pulmonary function, no
treatment was given. Differential blood counts, liver, renal
and thyroid function tests were within normal range [Add-
itional file 1: Table S1].
In June 2015, radiographic follow-up identified new
metastatic lesions in the liver, the abdominal wall, the pelvic
peritoneum, uterus and ovaries, spine and pelvic bones. On
the first of July, 2015, Nivolumab therapy was initiated at
3 mg/kg every 2 weeks for four cycles as part of a Phase II
study (BMS-936558). Repeated diffuse bleeding from meta-
static lesions in the abdominal cavity and macrohematuria
affecting the HB-level (Additional file 1: Table S1) required
red blood cell transfusions. Multiple brain metastases were
detected by computed tomography in the beginning of
September of 2015. The patient suffered from intense
nausea, head and neck pain and was treated with intraven-
ous opioids and corticoids. C-reactive protein levels were
elevated (250 mg/L) without fever. Laboratory values were
significant for anemia, neutrophilia, lymphopenia, reactive
thrombocytosis, moderately elevated aspartate aminotrans-
ferase (GOT), elevated thyroid stimulating hormone (TSH)
a b c
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Fig. 2 Morphological progression from initial diagnosis. a Melanoma ex naevo (08/2012) b local recurrence (08/2013) with deep in transit
metastasis and c sentinel node metastasis d skin metastasis (10/2014) e dedifferentiated melanoma at autopsy f intratumoral CD8-positive T-cell
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Fig. 3 Lung damage patterns. a CT Thorax: Pulmonary metastasis before therapy with Ipilimumab (02/2015) b CT Thorax: pulmonary metastasis
regression, ground glass opacities after Ipilimumab (04/2015) c sarcoid-like reaction d elastica stain showing epithelioid granulomas surrounded
by fibrotic rings e CD8-positive T-cell infiltrates surrounding giant cell granulomas as detected by immunohistochemistry f diffuse alveolar
damage; scale bars as indicated
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and lactate dehydrogenase (LDH) values. Peritoneal taps
were performed showing bloody ascites and elevated leuco-
cyte counts, consistent with spontaneous bacterial periton-
itis. Rapid progression of intraabdominal disease led to
ileus and renal failure. The patient deceased under best
supportive care. An autopsy was performed.
Autopsy findings
Partially necrotic, amelanotic melanoma metastases were
detected in brain, liver, soft tissues, small bowel, pelvic peri-
toneum, uterus and ovaries (Fig. 2e). Complete regression
of the pulmonary metastases, osseous metastases and skin
lesions was documented. A prominent intratumoral cyto-
toxic T-cell infiltrate with up to 100 CD8+ T-cells/mm2
(Fig. 2f), frequent expression of PD1 and cytotoxic granule-
associated RNA binding protein (TIA-1) (Additional file 5:
Figure S1) as well as a prominent histiocytic infiltrate and
tumor necrosis were noted in the majority of lesions
examined.
Histopathologic examination of the lungs revealed two
pathogenetically distinct tissue reaction patterns. First,
we observed panlobular histiocytic granulomas with
giant cells (Fig. 3c), perifocal interstitial lymphocytic
infiltrates and fibrotic rings (Fig. 3d) in both lungs with
an interlobular, peribronchiolar, and subpleural distribu-
tion. The perifocal lymphocytic infiltrate was rich in
CD8-positive T-cells (Fig. 3e) with frequent expression
of TIA-1 and PD-1. Central necrosis was absent. No in-
crease in eosinophils or mast cells was detected. Second,
an acute and multifocal pattern of diffuse alveolar dam-
age with formation of hyaline membranes was observed
in all pulmonary lobes (Fig. 3f ). No residual melanoma
cells were detected by S100 immunohistochemistry. The
patient history was non-significant for allergies or occu-
pational exposure to dust or silica. PAS and silver stains
for fungi as well as Ziehl-Neelsen stains for mycobacteria
were negative. Tissue based polymerase chain reaction
(PCR) analysis for mycobacteria, francisella tularensis,
bartonella henselae, CMV, HSV, VZV, EBV, mucor and
aspergillus were negative. Autoimmune and infectious
disease serology and tissue testing was negative (see
Additional file 2: Table S2).
Autopsy analysis of the heart demonstrated an age-
appropriate coronary status with isolated early stage ather-
omatous plaques (Fig. 4a). Histopathological examination
of the myocardium revealed patchy fibrosis and diffuse
mononuclear infiltrates (Fig. 4b) with up to 45 CD3-
positive lymphocytes/mm2 (normal range 5.3 ± 5.7/mm2
[19]) (Fig. 4c) and up to 18 CD68-positive macrophages/
mm2 (normal range 9.3 ± 4.3/mm2 [19]). Sixty five percent
of infiltrating lymphocytes expressed CD8. In CD8-positive
areas, up to 85 % of T-cells were PD-1 positive, 35 %
expressed TIA-1. No signs of vasculitis, no granulomas or
giant cells and no viral inclusions were detected. PCR-
based testing of the myocardium for bacteria, CMV, HSV,
VZV and EBV was negative. The patient had no clinical
history of cardiac disease. Examination of the liver demon-
strated a mildly increased portal and panlobular CD8-
predominant T-cell infiltration (Fig. 4d-e). Abundant sinus-
oidal CD68+ histiocytes with foam cell morphology and
formation of loose aggregates was noted (Fig. 4f). There
was no evidence of viral hepatitis, storage diseases, fatty
liver disease or cholangitis. No granulomas were detected.
Serology was negative for HIV, Hepatitis B and C. Screen-
ing tests for anti-nuclear antibodies and autoimmune











Fig. 4 Lymphocytic myocarditis and hepatic T-cell infiltration. a Normal-sized heart with normal coronary arteries in frontal view b patchy myocardial
fibrosis and mononuclear infiltrates c myocardial CD8-positive T-cell infiltrates as detected by immunohistochemistry e mild hepatic portal T-cell
infiltrates f lobular hepatic CD8-positive T-cell infiltrates and g sinusoidal infiltration by CD68+ histiocytic as detected by immunohistochemistry; scale
bars as indicated
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There was no history of a preexisting liver disease. A list of
stains performed and staining protocols can be found in
(Additional file 3: Table S3 and Additional file 4: Table S4).
Histopathologic examination of the brain was pertinent
for severe aseptic lymphocytic meningitis with extension
of mononuclear infiltrates into the brain parenchyma
(Fig. 5a). T-cell subtyping revealed that the lymphocytic
infiltrate predominantly consisted of CD8+ T-cells with
up to 180 CD8 + T-cells/mm2 detected in the meninges
and up to 15 CD8+ T-cells/ mm2 detected in the periven-
tricular brain parenchyma (Fig. 5b). Up to 45 % of T-cells
expressed PD-1, up to 60 % showed reactivity for TIA-1
(see Additional file 5: Figure S1) with a strong concomi-
tant CD68+ histiocytic infiltrate (Fig. 5c). There was no
evidence of viral inclusions, vasculitis or ischemic lesions.
The bone marrow was hypercellular with evidence of
diffuse lymphocytosis (Fig. 5d). Up to 15 % of all nucleated
cells in the bone marrow were CD3+ lymphocytes (Fig. 5e)
and up to 10 % were CD79+ B-cells. Interestingly, only
approximately 20 % of T-lymphocytes expressed CD8
(Fig. 5f). Analysis of endocrine organs including adrenals
and thyroid glands did not reveal any abnormalities.
Discussion
Immune checkpoint inhibition directed against PD-1 and
CTLA-4 has the potential to activate effector T-cells
against a wide spectrum of tumor- and self-antigens. The
present case demonstrates the importance of systematic
postmortem studies to identify relevant safety findings in
this setting. We illustrate that clinically overt irAEs may
be accompanied by a wide spectrum of unsuspected auto-
immune pathologies that require timely treatment. Both
pathologists and clinicians need to be increasingly aware
of the unique spectrum of immune related adverse drug
experiences for optimal patient management in daily
practice.
In patients with metastatic disease, a significant fraction
of tumor-antigen specific effector and memory T-cells
may be detectable in the tumor and peripheral circulation,
yet may be constrained by tumor-induced immune sup-
pression mechanisms. Targeting the PD-1/PD-L1 and
CTLA-4 signaling axis by immunomodulatory antibodies
can induce a significant anti-tumoral immune response.
However, therapeutic response to ipilimumab is accom-
panied by clinically detectable irAEs in up to 72 % of
patients with grade 3–4 irAEs in 24 % and lethal outcome
in 0.86 % of cases [11]. Onset of irAEs occurs on average
10 weeks after the onset of treatment and correlates with
dosage but can occur as late as 2 years after initialization
of treatment [11, 15]. In the landmark CheckMate 037
trial of nivolumab in advanced melanoma, irAEs have
been observed at a similar frequency of 68 % with less
common grade 3–4 events (9 %) [20]. This rate of grade 3
or 4 toxicity is similar to that seen with many chemothera-
peutic agents or targeted therapies [21]. The conducted
large clinical trials include a systematic assessment of
irAEs under anti-CTLA-4 and anti-PD-1 blockade. How-
ever, these analyses are primarily based on clinical, labora-
tory and radiographic evidence with few cases reporting
the analysis of tissue biopsies. Systematic autopsy studies
of patients treated with immune checkpoint inhibitors are
so far lacking in the literature.
This comprehensive autopsy study of a young patient
treated sequentially with ipilimumab and nivolumab dem-
onstrates that clinically or radiographically apparent organ
dysfunction may represent only a small part of treatment-
related unfavorable medical occurrences in a given case.
In particular, a sarcoid-like pulmonary reaction, features
100 µm
a b c
200 µm CD8 CD68200 µm
100 µm
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Fig. 5 Meningoencephalitis and bone marrow lymphocytosis. a Meningeal lymphocytosis with b a predominantly CD8+ T-cell infiltrate as demonstrated
by immunohistochemistry and c extension into the brain parenchyma; d Hypercellular bone marrow with e an increase in CD3+ and f CD8+
T-lymphocytes as detected by immunohistochemistry; scale bars as indicated
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of diffuse alveolar damage, aseptic meningoencephalitis
and myocarditis with myocardial damage were discovered
at autopsy as concomitant findings of a clinically sus-
pected immune-related pneumonitis. These findings were
classified as irAEs based on the close temporal associa-
tions between immune checkpoint inhibitor therapy and
histopathologic findings with a significant increase of CD8
+, TIA1+ and PD-1+ T-cells in the affected organs. Less
significant findings included hepatic lymphocytic infiltra-
tion and bone marrow lymphocytosis.
As the patient received both ipilimumab and nivolumab,
a definite association of a particular damage pattern to
one of the two agents is not possible in the present case.
However, the temporal association of the CT-graphic find-
ing of ground glass opacities after ipilimumab therapy
may favor an assignment of these pulmonary findings to
this agent. Indeed, CTLA4-related pneumonitis during
cancer immunotherapy has been previously described as a
rare event, but was diagnosed based on radiographic
assessment only [22]. We found a pattern of multifocal
diffuse alveolar damage with hyaline membranes under-
lying this radiographic finding. In addition, a pulmonary
sarcoid-like granulomatosis was identified. Previous CT-
scans and medical history was insignificant for sarcoidosis,
and post-mortem tissue based analysis ruled out an infec-
tious etiology. Interestingly, a similar occurrence following
CTLA-4 blockade has been described by other authors
[11, 23]. These findings may indicate that combined
checkpoint blockade may also cause superimposed histo-
pathological damage patterns as a correlate of distinct
immunological effects. Indeed, combination therapy leads
to divergent gene expression changes in T-cells and
monocyte populations that may underlie these specific
irAEs [24]. Immune checkpoint inhibitor therapy has been
linked to the uncontrolled release of cytokines in the form
of a cytokine storm [25]. While the typical symptoms of a
cytokine storm such as high fever, vasodilation, peripheral
edema and distributive shock were not detected in the
present case, cytokine release may have contributed to the
development of irAEs. In particular, interleukin-2 (IL-2)
secretion by activated T-cells is thought to play a role in
the pathogenesis of sarcoidosis [26] and may be a mech-
anism linking sarcoid-like granulomatous reactions to
immunotherapy. Indeed, the disease activity of a preexist-
ing sarcoidosis may also be increased by high dose IL-2
treatment of neoplasia [27] and human immunodeficiency
virus (HIV) infection [28]. Larger case series would be
desirable to further investigate the mechanistic link
between immune checkpoint inhibition and the develop-
ment of sarcoid-like irAEs.
Cardiac autopsy findings demonstrated a lymphocytic
myocarditis with patchy fibrosis in the absence of clinical,
serological or tissue-based evidence for an infectious eti-
ology. A non-infectious myocarditis in patients treated with
nivolumab [3, 29] and ipilimumab [4] has been previously
described, but biopsy studies are rare. Here we demonstrate
a pattern of diffuse lymphocytic infiltrates with a strong
predominance of CD8+/PD-1+/TIA1+ cytotoxic T-cells
and concomitant diffuse CD68+ histiocytic infiltrates.
These findings are reminiscent of a previous report includ-
ing analysis of a myocardial biopsy from a patient treated
with anti-PD-1 antibody (pembrolizumab) suggesting a
similar pathogenetic mechanism [16]. It is important to
note the potential pathophysiologic and clinical implica-
tions of concurrent lung and heart toxicity which may be
more severe and prone for critical events than either alone.
Brain autopsy revealed a severe aseptic lymphocytic
meningoencephalitis driven by CD8+/PD-1+ cytotoxic T-
cells. Aseptic meningitis has been reported in a patient
treated with ipilimumab [18] but histologic analysis has so
far been lacking. A range of neurological and endocrine
adverse events has been associated with immune check-
point inhibitors. Most frequently, autoimmune hypophysi-
tis and thyroidits is encountered with anti-CTLA-4
treatment [11]. In the present case, no tissue based, radio-
graphic or laboratory evidence of hypophysis or thyroid
dysfunction was present.
Other findings included a bone marrow lymphocy-
tosis and hepatic mononuclear and histiocytic infil-
trates. Hepatic toxicity and elevation of liver enzymes
has been described as a mostly low-grade irAE in pa-
tients treated with ipilimumab [11] and nivolumab
[20]. In a biopsy study, a pan-lobular hepatitis with
prominent sinusoidal histiocytic infiltrates and central
vein endothelialitis has been previously suggested as a
histologic clue to ipilimumab-associated hepatitis [30].
A bone marrow lymphocytosis has not been previ-
ously identified, but may be a concomitant feature of
generalized T-cell activation due to immune check-
point blockade. In the present case, no significant
hematological abnormalities in the peripheral blood
counts were detected.
Conclusion
Our results contribute to a better understanding of the
atypical immune toxicity associated with checkpoint in-
hibition by anti-CTLA-4 and anti-PD-1 antibodies. A dee-
per knowledge of these immune-related adverse events
and its multidisciplinary management will help to reduce
morbidity and therapy interruptions. Future perspectives
include the concurrent administration of antibodies tar-
geting CTLA-4 and PD-1. Our data underline that careful
monitoring is of particular importance in this setting to
identify potentially harmful immune pathology.
Consent
Written informed consent was given by the legal guard-
ians of the patient for publication of this case report and
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any accompanying images. A declaration of no objection
was obtained from the local ethics committee (Ethik-
kommission Nordwest- und Zentralschweiz (EKNZ); file
designation: UBE 15–106). A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
Additional files
Additional file 1: Table S1. Laboratory studies. Data on differential
blood counts, renal function, liver function tests and thyroid function
during each treatment cycle (dacarbazine, ipilimumab, nivolumab) are
provided. (DOCX 16 kb)
Additional file 2: Table S2. Autoimmune serology. Table showing the
screening results of autoimmune serology including systemic antibodies,
anti-neutrophil cytoplasmic antibodies (ANCA) and anti-neuronal
antibodies. (DOCX 16.8 kb)
Additional file 3: Table S3. Immunohistochemical stains. Systematic
overview of the immunohistochemical stains performed for each organ
and tumor specimen. (DOCX 21.3 kb)
Additional file 4: Table S4. Antibodies and staining protocols. All stains
were performed on a Leica BOND III / max autostainer platform (Leica
Bioystems, Muttenz, Switzerland). Information on antibody clones,
pretreatment and staining protocols is provided. (DOCX 18 kb)
Additional file 5: Figure S1. Expression of cytotoxic granule-associated
RNA binding protein (TIA-1) and programmed cell death protein 1 (PD-1,
nivolumab). Frequent expression of PD-1 and TIA-1 in tumor infiltrating T-cells
(A, B) and in lymphocytic infiltrates in the peripheral organs including the
meninges (C, D); scale bars as indicated. (PPTX 4.8 mb)
Abbreviations
ANCA: anti-neutrophil cytoplasmic antibodies; CD: cluster of differentiation;
CMV: cytomegalovirus; CTLA-4: cytotoxic T-lymphocyte-associated protein 4;
EBV: Epstein-Barr virus; FDA: Food and Drug Administration; HSV: herpes simplex
virus; irAEs: immune-related adverse events; NSCLC: non-small cell lung cancer
(NSCLC); PCR: polymerase chain reaction; PD-1: programmed cell death protein 1;
TIA-1: cytotoxic granule-associated RNA binding protein; VZV: varicella-zoster virus.
Competing interests
AZ received research funding from Roche Glycart, consultant fees and travel
grants from Roche, Bristol-Myers Squibb (BMS) and Merck, Sharp and Dohme
(MSD). SIR serves as an advisor for Roche, BMS and MSD, is principal investigators
for clinical trials led by Roche, BMS and MSD and received research funding and
travel grants from Roche. AW serves as an advisor for Roche, Merck, BMS, Novartis,
Lilly, Bayer, Amgen and AstraZeneca. All other authors report no financial and
non-financial competing interests.
Authors’ contributions
VHK performed the autopsy, the histopathological analysis, participated in
design and coordination of the study and drafted the manuscript. KDM
supervised the autopsy and histopathological analysis, oversaw design and
coordination of the study and drafted the manuscript. SIR treated the patient
at the University Hospital Basel, helped with rendering the diagnosis,
critically reviewed the manuscript and helped with revision of the paper. DZ
treated the patient at Kantonsspital Baselland, helped with rendering the
diagnosis and helped with revision of the paper. AW treated the patient at
the University Hospital Basel, helped with rendering the diagnosis, and
critically reviewed the manuscript and the revision of the paper. BW
reviewed and interpreted the radiographic images, helped with rendering
the diagnosis and critically reviewed the manuscript. AZ treated the patient
at the University Hospital Basel, helped with rendering the diagnosis and
critically reviewed the manuscript. MV treated the patient at Kantonsspital
Baselland, helped with rendering the diagnosis and critically reviewed the
manuscript. GC helped to analyze the histological sections, studied immune
infiltrates by immunostaining and reviewed the manuscript. NW helped to
analyze the histological sections, studied immune infiltrates by
immunostaining, critically discussed the case with VHK and KDM and
reviewed the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
We thank Dr. Sara Brittingham, MD for helpful discussions of the manuscript.
Author details
1Institute of Pathology, Cantonal Hospital Baselland, Mühlemattstrasse 11,
CH-4410 Liestal, Switzerland. 2Translational Research Unit (TRU), Institute of
Pathology, University of Bern, Murtenstrasse 31, CH-3010 Bern, Switzerland.
3Division of Medical Oncology, University Hospital Basel, Petersgraben 4,
CH-4031 Basel, Switzerland. 4Department of Medical Oncology, Cantonal
Hospital Baselland, Mühlemattstrasse 11, CH-4410 Liestal, Switzerland.
5Institute of Radiology, Cantonal Hospital Baselland, Mühlemattstrasse 11,
CH-4410 Liestal, Switzerland.
Received: 22 December 2015 Accepted: 9 February 2016
References
1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age.
Nature. 2011;480(7378):480–9. doi:10.1038/nature10673.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690.
3. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab
in previously untreated melanoma without BRAF mutation. N Engl J Med.
2015;372(4):320–30. doi:10.1056/NEJMoa1412082.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improved survival with ipilimumab in patients with metastatic melanoma. N
Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
5. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell
Lung Cancer. N Engl J Med. 2015;373(17):1627–39. doi:10.1056/
NEJMoa1507643.
6. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell
Lung Cancer. N Engl J Med. 2015;373(2):123–35. doi:10.1056/
NEJMoa1504627.
7. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S,
et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N
Engl J Med. 2015;373(19):1803–13. doi:10.1056/NEJMoa1510665.
8. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1
Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;
372(26):2509–20. doi:10.1056/NEJMoa1500596.
9. Silen W, Machen TE, Forte JG. Acid–base balance in amphibian gastric
mucosa. Am J Physiol. 1975;229(3):721–30.
10. Villasboas JC, Ansell SM. Nivolumab for the treatment of classical Hodgkin
lymphoma after failure of autologous stem cell transplant and Brentuximab.
Expert Rev Anticancer Ther. 2015. doi:10.1586/14737140.2016.1121812
11. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune
related adverse events associated with anti-CTLA-4 antibodies: systematic review
and meta-analysis. BMC Med. 2015;13:211. doi:10.1186/s12916-015-0455-8.
12. Postow M, Wolchok J. Toxicities associated with checkpoint inhibitor
immunotherapy. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA
(Accessed on December 15, 2015)
13. Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced
melanoma. J Hematol Oncol. 2015;8(1):123. doi:10.1186/s13045-015-0219-0.
14. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber J.
Nivolumab in Resected and Unresectable Metastatic Melanoma:
Characteristics of Immune-Related Adverse Events and Association with
Outcomes. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-1136.
15. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-Related
Pneumonitis during Cancer Immunotherapy. N Engl J Med.
2015;373(3):288–90. doi:10.1056/NEJMc1505197.
16. Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart
failure due to autoimmune myocarditis under pembrolizumab treatment for
metastatic melanoma. J Immunother Cancer. 2015;3:11.
doi:10.1186/s40425-015-0057-1.
Koelzer et al. Journal for ImmunoTherapy of Cancer  (2016) 4:13 Page 7 of 8
17. de Velasco G, Bermas B, Choueiri TK. Auto-immune arthropathy and
uveitis as complications from PD-1 inhibitor. Arthritis Rheumatol. 2015.
doi:10.1002/art.39406.
18. Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related
adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–80.
doi:10.1136/practneurol-2012-000447.
19. Bocchi EA, Tanigawa RY, Brandao SM, Cruz F, Issa V, Ayub-Ferreira S, et al.
Immunohistochemical quantification of inflammatory cells in
endomyocardial biopsy fragments after heart transplantation: a new
potential method to improve the diagnosis of rejection after heart
transplantation. Transplant Proc. 2014;46(5):1489–96.
doi:10.1016/j.transproceed.2013.12.062.
20. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who
progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised,
controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.
doi:10.1016/S1470-2045(15)70076-8.
21. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer
Therapy. J Clin Oncol. 2015;33(17):1974–82. doi:10.1200/JCO.2014.59.4358.
22. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after
allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–8.
doi:10.1182/blood-2008-07-168468.
23. Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, et al.
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol.
2012;30(17):e156–9. doi:10.1200/JCO.2011.39.3298.
24. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct
immunologic changes in vivo. J Immunol. 2015;194(3):950–9.
doi:10.4049/jimmunol.1401686.
25. Bakacs T, Mehrishi JN, Moss RW. Ipilimumab (Yervoy) and the TGN1412
catastrophe. Immunobiology. 2012;217(6):583–9. doi:10.1016/j.imbio.2011.07.005.
26. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis
and its clinical relevance. J Intern Med. 2003;253(1):18–30.
27. Logan TF, Bensadoun ES. Increased disease activity in a patient with
sarcoidosis after high dose interleukin 2 treatment for metastatic renal
cancer. Thorax. 2005;60(7):610–1. doi:10.1136/thx.2004.024018.
28. Blanche P, Gombert B, Rollot F, Salmon D, Sicard D. Sarcoidosis in a patient
with acquired immunodeficiency syndrome treated with interleukin-2. Clin
Infect Dis. 2000;31(6):1493–4. doi:10.1086/317475.
29. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's
lymphoma. N Engl J Med. 2015;372(4):311–9. doi:10.1056/NEJMoa1411087.
30. Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al.
Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a
Series of 11 Cases. Am J Surg Pathol. 2015;39(8):1075–84. doi:10.1097/PAS.
0000000000000453.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Koelzer et al. Journal for ImmunoTherapy of Cancer  (2016) 4:13 Page 8 of 8
